3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Salivary Gland Neoplasms
1
Prostate Adenocarcinoma
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
High-Risk Localized Prostate Cancer
×
darolutamide
×
30 days
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled